Seeking Alpha

Michael Becker

 
View as an RSS Feed
View Michael Becker's Articles BY TICKER:
  • Medical Advances May Help Improve Psoriasis Outcomes
    Nov. 11, 2012 CELG, NVS, IDRA 3 Comments
  • Thinking Of Spring: Tulips And Cancer Stem Cell Mania
    Mar. 5, 2012 ENMD, GERN, IMUC 2 Comments
  • Rethinking Immunotherapy For Brain Tumors
    Feb. 24, 2012 AGEN, CLDX, DNDN 6 Comments
  • 2011 Review And Outlook For Biotechnology In 2012
    Jan. 25, 2012 AKRX, DNDN, MDVN 2 Comments
  • 2012 Preview: Cancer Immunotherapy Catalysts
    Dec. 15, 2011 DNDN, AGEN, CELG 20 Comments
  • Baker's Dozen Trying To Beat The Odds In Pancreatic Cancer
    Oct. 25, 2011 CELG, AMGN, THLD 6 Comments
  • Adjuvants May Hold Key To Unlocking Cancer Immunotherapy Revolution
    Sep. 20, 2011 AGEN, CLDX, IDRA 12 Comments
  • Advances in Radiation Therapy and Related Cancer Stocks
    Jul. 29, 2011 CBLI, AZN Comment!
  • Cancer Immunotherapy: A Roundtable Discussion
    Jun. 30, 2011 BIIB, GNMSY, GSK 6 Comments
  • 3 Late-Stage Leukemia Company Previews for ASCO 2011
    May. 9, 2011 ASTX, CYCC, SNSS Comment!
  • Similarities Between the First Two Active Immunotherapies in Cancer
    Mar. 30, 2011 DNDN, BMY, MDVN Comment!
  • Ipilimumab Approval Highlights Active Immunotherapy Renaissance
    Mar. 27, 2011 BMY, DNDN, CLDX 13 Comments
  • Earthquake Highlights Opportunity for Treating Radiation Sickness
    Mar. 14, 2011 OSIR, CBLI, AMGN 13 Comments
  • To Partner or Not to Partner: That Is the Question
    Editors' Pick • Mar. 10, 2011 CLDX, PFE, RHHBY 13 Comments
  • Do Mergers Mean Billions for Biotech?
    Editors' Pick • Feb. 16, 2011 SNY, AMGN, BIIB 2 Comments
  • Warning Biotech Investors: FDA Advisory Panels' No Means No, Yes Means Maybe
    Feb. 7, 2011 OREX, ITMN, MELA 5 Comments
  • Biotech Merger/Acquisition Activity Mixed During Major Conference
    Jan. 18, 2011 CTIC, ACAD, CLSN 1 Comment
  • Biotech’s Top and Bottom 10 From 2010
    Jan. 6, 2011 BTK, NBI, DIA 3 Comments
  • Drug Development Spotlight: The mTOR's New Clothes?
    Nov. 23, 2010 AEZS, PGNX, EXEL 5 Comments
  • Amgen, Celgene and Novartis in the Fight Against Pancreatic Cancer
    Editors' Pick • Oct. 26, 2010 AAPL, CELG, AMGN 7 Comments
  • Investment Opportunities in AML Frontline Therapies
    Sep. 7, 2010 ASTX, CELG, SGEN 7 Comments
  • Stem Cell Competition Heating Up
    Aug. 25, 2010 GERN, STEM, ASTM 8 Comments
  • Monoclonal Antibody Companies Command Premiums
    Jul. 12, 2010 IMGN, IMMU, MITI 2 Comments
  • Five Key Factors Weighing on Dendreon
    Jul. 2, 2010 DNDN, LLY, SNY 50 Comments
  • Cyclin-Dependent Cancer Confab Preview
    Apr. 17, 2010 CYCC, SNSS, PFE 1 Comment
  • 7 Companies in the Race to Find Cures for Cancer
    Editors' Pick • Apr. 8, 2010 DNDN, AGEN, VICL 10 Comments
  • For Biotech in 2010, It's Déjà Vu All Over Again
    Mar. 8, 2010 MNKD, ITMN, ALKS 4 Comments
  • BMT Tandem Meetings Review: Gut Check Time for Graft-Versus-Host Disease Companies
    Mar. 1, 2010 OSIR, CELG Comment!
  • Iron Safety Hits AMAG Pharmaceuticals
    Editors' Pick • Feb. 4, 2010 AMAG, ACT 6 Comments
  • Biotech Deal Activity Slows - The Pause that Refreshes?
    Jan. 17, 2010 CEPH, AMGN, MDT Comment!
  • Biotech’s 2009 Stealth Small Cap Rally
    Jan. 4, 2010 AMGN, BIIB, CELG 1 Comment
  • Graft-Versus-Host Disease: Failures and Future Opportunities
    Dec. 10, 2009 OSIR, CYCC, XOMA Comment!